239 related articles for article (PubMed ID: 31488714)
1. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.
Ge C; Huang H; Huang F; Yang T; Zhang T; Wu H; Zhou H; Chen Q; Shi Y; Sun Y; Liu L; Wang X; Pearson RB; Cao Y; Kang J; Fu C
Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19635-19645. PubMed ID: 31488714
[TBL] [Abstract][Full Text] [Related]
2. A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
Shi Y; Wang X; Meng Y; Ma J; Zhang Q; Shao G; Wang L; Cheng X; Hong X; Wang Y; Yan Z; Cao Y; Kang J; Fu C
Adv Sci (Weinh); 2021 Nov; 8(21):e2101936. PubMed ID: 34605226
[TBL] [Abstract][Full Text] [Related]
3. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
Muñoz M; Coveñas R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
[TBL] [Abstract][Full Text] [Related]
4. Substance P prevents 1-methyl-4-phenylpyridinium-induced cytotoxicity through inhibition of apoptosis via neurokinin-1 receptors in MES23.5 cells.
Wang SY; Chen L; Xue Y; Xia YJ
Mol Med Rep; 2015 Dec; 12(6):8085-92. PubMed ID: 26497672
[TBL] [Abstract][Full Text] [Related]
5. MiR-21 in Substance P-induced exosomes promotes cell proliferation and migration in human colonic epithelial cells.
Bakirtzi K; Man Law IK; Fang K; Iliopoulos D; Pothoulakis C
Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G802-G810. PubMed ID: 31545921
[TBL] [Abstract][Full Text] [Related]
6. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
7. The neurokinin 1 receptor regulates peritoneal fibrinolytic activity and postoperative adhesion formation.
Cassidy MR; Sheldon HK; Gainsbury ML; Gillespie E; Kosaka H; Heydrick S; Stucchi AF
J Surg Res; 2014 Sep; 191(1):12-8. PubMed ID: 24836694
[TBL] [Abstract][Full Text] [Related]
8. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M
Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755
[TBL] [Abstract][Full Text] [Related]
9. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.
Li X; Ma G; Ma Q; Li W; Liu J; Han L; Duan W; Xu Q; Liu H; Wang Z; Sun Q; Wang F; Wu E
Mol Cancer Res; 2013 Mar; 11(3):294-302. PubMed ID: 23345604
[TBL] [Abstract][Full Text] [Related]
10. Advances in the research and application of neurokinin-1 receptor antagonists.
Hong X; Ma J; Zheng S; Zhao G; Fu C
J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
[TBL] [Abstract][Full Text] [Related]
11. Human microglia and astrocytes constitutively express the neurokinin-1 receptor and functionally respond to substance P.
Burmeister AR; Johnson MB; Chauhan VS; Moerdyk-Schauwecker MJ; Young AD; Cooley ID; Martinez AN; Ramesh G; Philipp MT; Marriott I
J Neuroinflammation; 2017 Dec; 14(1):245. PubMed ID: 29237453
[TBL] [Abstract][Full Text] [Related]
12. Elevated SP/NK-1R in esophageal carcinoma promotes esophageal carcinoma cell proliferation and migration.
Dong J; Feng F; Xu G; Zhang H; Hong L; Yang J
Gene; 2015 Apr; 560(2):205-10. PubMed ID: 25659767
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
[TBL] [Abstract][Full Text] [Related]
14. Differential contribution of substance P and neurokinin A to spinal cord neurokinin-1 receptor signaling in the rat.
Trafton JA; Abbadie C; Basbaum AI
J Neurosci; 2001 May; 21(10):3656-64. PubMed ID: 11331395
[TBL] [Abstract][Full Text] [Related]
15. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
[TBL] [Abstract][Full Text] [Related]
16. SP/NK-1R promotes gallbladder cancer cell proliferation and migration.
Deng XT; Tang SM; Wu PY; Li QP; Ge XX; Xu BM; Wang HS; Miao L
J Cell Mol Med; 2019 Dec; 23(12):7961-7973. PubMed ID: 30903649
[TBL] [Abstract][Full Text] [Related]
17. The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma.
Muñoz MF; Argüelles S; Rosso M; Medina R; Coveñas R; Ayala A; Muñoz M
Biomed Res Int; 2022; 2022():6291504. PubMed ID: 35434136
[TBL] [Abstract][Full Text] [Related]
18. Substance P (SP)-neurokinin-1 receptor (NK-1R) alters adipose tissue responses to high-fat diet and insulin action.
Karagiannides I; Stavrakis D; Bakirtzi K; Kokkotou E; Pirtskhalava T; Nayeb-Hashemi H; Bowe C; Bugni JM; Nuño M; Lu B; Gerard NP; Leeman SE; Kirkland JL; Pothoulakis C
Endocrinology; 2011 Jun; 152(6):2197-205. PubMed ID: 21467195
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin-1 receptor expression and antagonism by the NK-1R antagonist maropitant in canine melanoma cell lines and primary tumour tissues.
Borrego JF; Huelsmeyer MK; Pinkerton ME; Muszynski JL; Miller SA; Kurzman ID; Vail DM
Vet Comp Oncol; 2016 Jun; 14(2):210-24. PubMed ID: 24751104
[TBL] [Abstract][Full Text] [Related]
20. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
